What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
The scientist’s investigation covers issues in Surgery, Lung cancer, Internal medicine, Complication and Genotype.
The concepts of his Surgery study are interwoven with issues in Stenosis and Radiology.
His Lung cancer study combines topics from a wide range of disciplines, such as Cancer research, Carcinoma, Immunology and Adenocarcinoma.
He has researched Internal medicine in several fields, including Gastroenterology, Physical therapy and Oncology.
His study in Genotype is interdisciplinary in nature, drawing from both Allele and DNA repair.
His Pathology research incorporates themes from Bronchoalveolar lavage and Idiopathic pulmonary fibrosis.
His most cited work include:
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2242 citations)
- Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. (1001 citations)
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (932 citations)
What are the main themes of his work throughout his whole career to date?
John C. Wain mainly investigates Surgery, Internal medicine, Lung cancer, Immunology and Lung.
His studies in Surgery integrate themes in fields like Respiratory disease and Carcinoma.
John C. Wain interconnects Gastroenterology, Oncology and Pathology in the investigation of issues within Internal medicine.
His Lung cancer research incorporates elements of Cancer, Adenocarcinoma, Cancer research, Confidence interval and Genotype.
His work deals with themes such as Lung transplantation, Transplantation and Miniature swine, which intersect with Immunology.
John C. Wain focuses mostly in the field of Airway, narrowing it down to matters related to Stenosis and, in some cases, Intubation.
He most often published in these fields:
- Surgery (39.68%)
- Internal medicine (28.89%)
- Lung cancer (24.76%)
What were the highlights of his more recent work (between 2010-2021)?
- Surgery (39.68%)
- Pathology (15.87%)
- Internal medicine (28.89%)
In recent papers he was focusing on the following fields of study:
His primary scientific interests are in Surgery, Pathology, Internal medicine, Lung cancer and In vivo.
The Surgery study combines topics in areas such as Esophagectomy and General surgery.
In the field of Pathology, his study on Rociletinib and EGFR Activating Mutation overlaps with subjects such as T790M.
His studies deal with areas such as Genotyping, GSTP1, Genotype and Oncology as well as Internal medicine.
He has included themes like Cancer research, COPD, Carcinoma, Adenocarcinoma of the lung and Lung in his Lung cancer study.
His Lung research is multidisciplinary, incorporating elements of Immunology, Chemokine, Immune tolerance and Isoflurane.
Between 2010 and 2021, his most popular works were:
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors (2242 citations)
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers (932 citations)
- Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice (283 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
Surgery, Esophagectomy, Anastomosis, Lung cancer and Cancer research are his primary areas of study.
His research in Surgery intersects with topics in Metastasectomy, Sarcoma and Cohort.
His Anastomosis research includes elements of Laryngectomy, Swallowing and Fistula, Tracheoesophageal fistula.
His Lung cancer research is multidisciplinary, relying on both Genetics, Carcinoma and Lung.
John C. Wain combines subjects such as Carcinogenesis, Anaplastic lymphoma kinase, ALK inhibitor, Genome instability and Molecular biology with his study of Cancer research.
John C. Wain studies Cancer, a branch of Internal medicine.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
